Sentences with phrase «years of therapy with»

«We have been through years of therapy with our son.

Not exact matches

From a value perspective, if the young adults with leukemia who respond to therapy end up with more years of life — an outcome that is quite likely — then Kymriah will be cost - effective for society as well.

With over 25 different forms of yoga and 122 meditation therapies, the company has gained a lot of traction in four years

Gene therapy has been on a roll in the past year, with the FDA approving Spark Therapeutics» landmark gene therapy for an inherited form of blindness in December.

Outlook: According to Employment and Social Development Canada, audiologists and speech - language pathologists (part of the «therapy and assessment professionals» occupation class) should find a fairly balanced job market into 2020, with the number of job seekers nearly matching the number of available positions over the next few years.

Swiss pharmaceutical giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

giant Novartis has made waves with a drug pipeline that includes one of the most talked - about experimental cancer therapies in recent years — a treatment called Kymriah that reconfigures the body's own immune cells to become aggressive blood - cancer killers.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

The company is also seeking deeper inroads into rare diseases, with a number of assets in late - stage development, and last year it scored a major regulatory win when Europe approved its «bubble boy syndrome» gene therapy Strimvelis.

Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

Both Keytruda and Opdivo have price tags of around $ 150,000 a year without being combined with other therapies.

Phoundry enhances Intarcia's internal efforts to build upon the differentiated clinical success of its Phase 3 investigational therapy, ITCA 650, the first injection - free GLP - 1 therapy with the potential to deliver up to a full year of treatment from a single placement.

Five years ago, we began collaborating with the University of Pennsylvania and invested in further developing and bringing what we believed would be a paradigm - changing immunocellular therapy to cancer patients in dire need.

With major clinical successes in areas such as CAR - T, gene therapy, immune - oncology, cell therapy and gene editing, many see 2017 as the year that biotech really came of age.

Dendreon was first - to - market with its activated cellular therapy, Provenge ® in 2010 followed by a 7 year gap until Novartis» Kymriah ® was approved in August of 2017 which was shortly followed up by the approval of Kite Pharma's Yescata ® in November of 2017.

Incyte's (NASDAQ: INCY) Jakafi racked up $ 1.1 billion in sales last year as the only targeted therapy for patients with myelofibrosis, but a majority of patients who take it eventually relapse.

Combine this with dozens of oncology and ant - inflammatory collaborations for potentially first - in - class therapies, and you have a recipe for double - digit annual sales growth for years to come.

Over the last 60 years the profession has progressed in the United States (and throughout the world), with the development of standards of training and a body of research to guide credentialed practitioners in the ethical practice of art therapy.

Going on 4 years of therapy trying to deal with it.

Ever since her story was featured in Christianity Today nearly a year ago, Butterfield has become something of a celebrity within the conservative evangelical world, and every time I'm in conversation with someone about the potential dangers of «conversion therapy» (which seeks to change a person's sexual orientation through counseling and prayer), her name invariably comes up.

After a year and a half of group therapy, of steering clear of the lifers and other hardened criminals who lived in the same cellblocks with addicts and of playing basketball in the prison yard, Manigault was paroled.

Jonny, now about eight years old, lives in San Francisco with Cris Cohen and Jennifer Long, longtime pit bull rescue volunteers, who quickly recognized his way with children and had him certified as a therapy dog within a year of taking him in.

After Vick and others were convicted on federal charges of trafficking and sponsoring fighting dogs, Jonny won a Most Beautiful Dog in the Country contest in 2012, had a Gund plush toy created in his likeness and last week was recognized for his work as a therapy dog with a new award: ASPCA Dog of the Year.

I'm fourteen years old starting my road to recovery and it's very fearing and to know that I have to live with it scares the living daylight a out of me I can't speak much about my cognitive behavior therapy because I've only really doing assements but I'm writing this for myself and yourself I haven't always been religious but in times of fear and need know that you aren't alone God is always there and even wen your in your worse state I usally just lay down meditate a bit and speak to my father God and he always gives me a sense of relief this past week I feel like I have been a constant circle of fear but I would always freak out and be scared for no reason but just know that more than 44 million people have this you are br alone and one day you will meet your savior Jesus christ he put you in a test of life and he's going to congratulate you, you must wait for him and on another note if any one knows how to deal with the fear of the future or staying in a constant state please email me at [email protected] thank you so much everyone and there is a recovery maybe but today or Tommie but you will overcome

Well, some very exceptional adoptive parents I know do, but most of the selfish rest of us don't wake up and say - wow, I'd really like to go to lots and lots of therapy with my five - year - old until I'm so harried that I need some for myself as well.

A 30 - year - old transgender woman, who had been receiving feminizing hormone therapy for 6 years, was able to induce lactation by using a breast pump along with a combination of domperidone, estradiol, and progesterone.

With 25 years post-graduate training and advanced level certifications, Wendy Behary is the founder and director of The Cognitive Therapy Center of New Jersey and The New Jersey Institute for Schema Therapy.

Allie Bowne Schreiner is a licensed marriage and family therapist with over nine years of experience practicing therapy with children, adolescents, adults and families and 20 years of experience working with children and families in various capacities.

I've used them with infants in early intervention therapy, and they have also come in handy for promoting my own son's development during his first years of life.

I have not had any concerns about the safety of the OBall in my 3 years of owning mine and using it with both my own children and my therapy clients.

I'm starting with baby steps — daily early AM exercises at home and physical therapy 2x a week to heal my back, wrecked from hours and hours of hunching over a computer and a few rear - end car accidents last year.

This week, we hear from our newest expert about the field of occupational therapy, and from our sleep expert on working with the nap / no nap schedule of a two - year - old.

Dr. Schoen is an Occupational Therapist with 28 years of clinical experience and a doctorate in Occupational Therapy from New York University (2001).

Any survivor — even one with years of therapy behind her — can feel distress during pregnancy and birth, but that doesn't mean they haven't worked hard enough to heal.

Although I have worked with couples in a variety of formats over many years — birth and parent preparation, The Birth Empowerment Workshop ®, and relationship counselling and therapy — I have recently become a Certified Becoming Us ™ Facilitator, which has really upped my game for helping couples navigate the transition as they grow from partners into parents.

Using a blend of professional objectivity, evidence - based research, and personal, straight - forward suggestions gathered from years of experience, this book brings the reader into the private world of therapy with the postpartum woman.

With these new board members, as well as the work of APT, I am excited and hopeful that the next two years will be full of growth for Play Therapy — across the entire state.

Kellner, who was diagnosed with cerebral palsy as an infant and underwent many operations and years of physical therapy, has become a leading voice in New York on disability issues.

A single dose of the drug zoledronic acid was found to inhibit the bone loss that is common in HIV - infected patients and that is increased during the first two years of treatment with antiretroviral therapy (ART).

Fong, a physician and astrophysicist who trained in part at NASA, weaves firsthand, nail - biting ER experiences with gripping historical narrative as he recounts 100 years of breakthroughs, such as inducing hypothermia as life - saving therapy and pioneering facial reconstruction for burn victims.

The investigators caution the approach is years away from use in humans, but gene therapy carries the promise of restoring hearing in people with several forms of both genetic and acquired deafness.

Gene therapy, generally, has been the holy grail of gene - based therapeutics since the 1980s, with just a sprinkling of individual successes over the years.

For men with intermediate risk prostate cancer, side effects at two years following radiation therapy (RT) were comparable for extremely - hypofractionated treatment, which was delivered in seven fractions across two and a half weeks, and conventional treatment of 39 fractions across eight weeks, according to research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO).

But we still have a long way to go before we will have affordable therapies able to prolong survival from advanced melanoma by several years with a decent quality of life.»

Despite various approaches and years of pre-clinical studies, effective, mechanism - based therapies to assist with cocaine abuse and dependence are still sorely lacking.

For example, in the combined hormone therapy trial, treated 50 - to 59 - year - olds had five additional cases of heart disease and five more strokes per 10,000 women annually compared with the same - aged group on placebo.

Ten years after infection with HIV, a typical person has progressed to where tens if not hundreds of thousands of copies of the virus can be found in a single milliliter of their blood and more than three quarters of their CD4 immune cells are destroyed, if they have not started drug therapy.

It typically takes many years to initiate such trials because of the stringent safety testing that must be done before testing in humans begins, but Reynolds said it may be possible to move faster as the therapy only involves modifying a patient's dietary intake and supplementing with a medium - chain triglyceride oil, both of which have no known side effects.

In April of this year, the team reported that patients responded well, with no serious complications, suggesting the therapy might also work for face transplants.

A three - year randomized controlled clinical trial has found that two topical creams are effective in most primary, low - risk superficial BCC, comparing favorably with photodynamic therapy (PDT), as reported by investigators in the Journal of Investigative Dermatology.